Skip to Content
Morningstar
Get 14 Days Free

Mallinckrodt PLC MNKKQ

Morningstar Rating
Rating as of

Morningstar’s Analysis

There is no Morningtar’s Analysis data available.

Company Profile

Business Description

Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands that includes innovative specialty pharmaceutical brands; and Specialty Generics that includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of revenue from the United States.

Contact
College Business and Technology Park, Cruiserath
Dublin, 15, Ireland
T +353 16960000
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 25, 2021
Stock Type —
Employees 3,100

Related

Fund Spy
The Year in U.S. Equity Funds, 2019
A very good year for the market.
Nick Watson
Fund Spy
Trying to be Large-Value in a Large-Growth World
How four large-value Morningstar Medalists have fared in the growth-led market.
Tony Thomas
Stock Strategist Industry Reports
What Opioid Litigation Means for Healthcare Stocks
It continues to inflict pain on drug manufacturers and distributors.
Soo Romanoff
Commentary
Investors Pressure Firms on Opioid Crisis
Five types of opioid-related shareholder resolutions are currently on ballots.
Jackie Cook
Investing Specialists
Morningstar Runs the Numbers
We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended Aug. 18.
Morningstar.com
Investing Specialists
Morningstar Runs the Numbers
We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended Aug. 11.
Morningstar.com
Stock Strategist Industry Reports
Generic Drug Industry Headwinds Lead to Moat Downgrades
Fear could create opportunity, but we advise investors to proceed with caution.
Michael Waterhouse
Stock Strategist
Drug Pricing Power Transcends Politics
Although some proposals could trim growth prospects, they shouldn’t have a major impact on more innovative drugs.
Damien Conover
Our Picks
Looking for Bargains? Check Out High-Quality Healthcare Stocks
Drug pricing concerns have indiscriminately weighed on healthcare stocks; these names look undervalued.
Karen Wallace
Stock Analyst Update
Clinton Drug Plan No Threat to Innovators
If the plan were to take shape, less innovative generic drugs and older branded drugs would be the likely targets for price controls.
Damien Conover
Stock Strategist Industry Reports
Healthcare's Latest Prognosis
Emerging from a third-quarter pullback, healthcare companies are preparing for the next phase of the Affordable Care Act.
Rob Wherry
Our Picks
2014's Biggest Stock Winners: Is There Any Gas Left in the Tank?
Declining fuel prices stoked great returns at several of these companies, but that's not a lasting advantage.
Christine Benz
Quarter-End Insights
Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns
As credit spreads have tightened on a nearly continuous trend over the past year, they are becoming richly valued relative to their historical average.
David Sekera
Investing Specialists
Ideas From the Wide Moat Focus Index
Morningstar StockInvestor editor Matt Coffina discusses recent additions to the Wide Moat Focus Index.
Matthew Coffina
Credit Insights
Credit Spreads Remain Range-Bound
We are seeing an increase in idiosyncratic catalysts that are specific to an individual issuer as opposed to industry factors that affect an entire sector.
David Sekera